Skip to content
CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Clinical Accelerator
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs

    Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…

    December 28, 2017| Arthur N. Brodsky, PhD
  • Recent FDA Announcements Herald Advances in Personalized Approaches Against Cancer

    Two tumor-profiling tests recently authorized by the FDA enable doctors to tailor their treatments more effectively to…

    December 22, 2017| Arthur N. Brodsky, PhD
  • Immunotherapy Shines at ASH and ESMO IO Conferences

    Two conferences, one in America and one in Europe, highlight immunotherapy's continued progress and the important contributions…

    December 15, 2017| Arthur N. Brodsky, PhD
  • Trusted Charities for Holiday Giving

    Trusted consumer watchdog organizations make it a little easier to decide where to give this holiday season with…

    December 13, 2017| Caitlin Mackaman
  • Cindy Stowell Continues to Inspire

    Jeopardy! host Alex Trebek will make a special announcement on Tuesday, November 7th. 

    November 6, 2017| Alice Northover
  • CRI Researcher Highlights New Technique to Aid Immunotherapy

    Dr. Mohammad Rashidian’s nanobodies could help improve doctors’ decisions regarding immunotherapy.

    October 26, 2017| Arthur N. Brodsky, PhD
  • Corporate Social Responsibility Gives Cancer Immunotherapy Research a “Wonderful Edge”

    Cupid Intimates spearheaded a corporate social responsibility initiative that generated a $10,000 donation to CRI’s immunotherapy research…

    October 23, 2017| Marla Lawson
  • CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients

    FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.

    October 18, 2017| Arthur N. Brodsky, PhD
  • CRI featured in USA Today’s End-of-Year Charity Giving Advice

    CRI among 12 top-rated cancer charities within a subset of organizations doing good work in breast cancer…

    October 6, 2017| Marla Lawson
Previous Page
1 … 62 63 64 65 66 … 98
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Uniting for a World
Immune to Cancer

Stay Up To Date

Get Patient Stories & Research Updates


Donate By Mail

Cancer Research Institute
29 Broadway, Floor 4
New York, NY 10006-3111

Quick Links

  • Our Annual Impact
  • Blog
  • Careers
  • Contact Us
  • Donate

Trusted & Top-Rated charity

Charity Navigator
Candid Platinum Transparency 2026
Charity Watch Top Rated
BBB Accredited Business

connect with Us

LinkedIn icon
Facebook Icon
X icon
Instagram icon
YouTube icon

The Cancer Research Institute is a 501(c)(3) charitable organization. Our Federal Tax ID Number is 13-1837442.

©2026 Cancer Research Institute

*Immunotherapy results may vary from patient to patient.

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
Trigger Donate Modal